|Articles|October 14, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
2
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
3
HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges
4
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
5